Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)

Int J Infect Dis. 2022 Nov:124:190-198. doi: 10.1016/j.ijid.2022.09.032. Epub 2022 Sep 28.

Abstract

Objectives: SARS-CoV-2 is primarily transmitted within households, with massive healthcare system burdens. The role of inactivated vaccines and ChAdOx1 nCoV-19 vaccination in the prevention of within-household transmission remains unknown.

Methods: This observational case-control study tracked 408 SARS-CoV-2 polymerase chain reaction-confirmed index cases from April to September 2021. This study aimed to prove the benefit of inactivated and ChAdOx1 nCoV-19 vaccinated index cases in preventing within-household transmissibility.

Results: A total of 1178 household contacts were investigated. A total of 231 index cases were vaccinated with inactivated or ChAdOx1 nCoV-19 vaccine, and 177 were unvaccinated. The vaccinated index cases exhibited a 7.8% risk reduction in household transmission. There was no difference in the secondary attack rate of 50.77% in unvaccinated cases compared with 46.81% in vaccinated index cases (P-value = 0.177). Those who completed the two-dose SARS-CoV-2 vaccination demonstrated a 93% reduction in household transmissibility within 14-90 days. The effectiveness for preventing household transmission was 26.09%. The 87% reduced risk of household transmissibility was observed among those who wore masks.

Conclusion: The completed two-dose SARS-CoV-2 inactivated and ChAdOx1 nCoV-19 vaccination within 14-90 days among index cases demonstrated benefits in preventing within-household transmissibility. Implementing high-efficacy vaccination and an appropriate booster dose can prevent household transmission.

Keywords: COVID-19; ChAdOx1 nCOV-19; Household transmission; Inactivated vaccine; SARS-CoV-2.

Publication types

  • Observational Study

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Case-Control Studies
  • ChAdOx1 nCoV-19
  • Humans
  • SARS-CoV-2
  • Thailand / epidemiology
  • Vaccination
  • Vaccines, Inactivated

Substances

  • COVID-19 Vaccines
  • ChAdOx1 nCoV-19
  • Vaccines, Inactivated